A Phase 1 interventional study of Ferric maltol capsule and Ferric maltol suspension in Anemia, Iron Deficiency, sponsored by Shield Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Shield Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing ferric maltol in Anemia, Iron-Deficiency — none open to participants now, none under way, none of them phase 3. ferric maltol · Anemia, Iron-Deficiency.
Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 8th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →None of the 12 studies testing ferric maltol in Anemia, Iron-Deficiency is open now. The open studies under Anemia, Iron-Deficiency, anywhere →
ferric maltol: first FDA approval 2019 (ACCRUFER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 78 across the 12 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 4 most frequent:
Shield Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Shield Therapeutics has 8 studies filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the Pharmacokinetics (PK) of the new ferric maltol suspension, in adults, with the existing ferric maltol capsule.
Open-label, Phase 1, four way crossover study to compare the PK of the new ferric maltol suspension, in healthy volunteers, with the existing ferric maltol capsules under fed and fasted conditions.
32 subjects will be randomised to 1:1:1:1 ratio to receive one of the treatment sequences.
Based on the randomised sequence, subjects will receive a single dose of 30mg ferric maltol capsule in a fed/ fasted condition and 30 mg (5ml) ferric maltol suspension in a fed/ fasted condition.
Subject participation in the study will consist of 3 periods:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All of the following criteria must be met for a subject to participate in the study:
Female subjects of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of until study completion and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as hormonal contraception (oral, implants, injection, ring, or patch) and intrauterine contraceptive devices (IUDs), at least 3 months prior to Screening, or a vasectomized partner.
Note: complete abstinence from sexual intercourse is an acceptable form of contraceptive practice.
Male subjects with partners of childbearing potential must have had surgical sterilization (vasectomy) at least 26 weeks prior to Screening or use a male barrier method of contraception (i.e. male condom with spermicide) during any sexual intercourse from Study Day -1 (beginning of confinement) until 3 months after the Follow-up Visit.
Note: Complete abstinence from sexual intercourse is an acceptable form of contraceptive practice.
Exclusion Criteria:
A subject who meets any of the following criteria is not eligible for participation in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of 30 mg ferric maltol capsule in a fed condition
Drug: Ferric maltol capsule
Single dose of 30 mg ferric maltol capsule in a fasted condition
Drug: Ferric maltol capsule
Single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition
Drug: Ferric maltol suspension
Single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition
Drug: Ferric maltol suspension
single dose of 30 mg capsule
Also known as: ST10, Feraccru, Accrufer
single dose of 30mg (5ml) oral suspension
Also known as: ST10
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted Condition
Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fasted condition between ferric maltol capsule and ferric maltol suspension.
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fasted condition
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Combined Periods of Fed Condition
Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fed condition between ferric maltol capsule and ferric maltol suspension
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fed condition
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fasted Condition
Ratio of area under the curve (AUClast) of total serum iron in combined periods of fasted condition between ferric maltol capsule and ferric maltol suspension
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fasted condition
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fed Condition
Ratio of area under the curve (AUClast) of total serum iron in combined periods of fed condition between ferric maltol capsule and ferric maltol suspension
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in combined fed condition
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Capsule
Ratio of maximum serum concentration (Cmax) of total iron in fasted vs fed condition in 30mg ferric maltol capsule
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose on both PK days
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Capsule
Ratio of area under the curve (AUClast) of total serum iron in fasted vs fed condition in 30 mg ferric maltol capsule
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in both PK days
Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Suspension
Ratio of maximum serum concentration (Cmax) of total iron in fasted vs fed condition in 30mg (5ml) ferric maltol suspension
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose on both PK days
Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Suspension
Ratio of area under the curve (AUClast) of total serum iron in fasted vs fed condition in 30mg (5ml) ferric maltol suspension
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose in both PK days
PK Analysis of Total Serum Iron Concentration; AUCinf in Fasted and Fed Conditions
Descriptive statistics of total serum iron concentration; Area Under the Curve (AUCinf) by formulation (suspension or capsule) and condition (fed and fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Baseline Corrected Serum Iron Concentration; Cmax in Fasted and Fed Conditions
Descriptive statistics of baseline corrected serum iron concentration; Maximum Concentration (Cmax), by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Baseline Corrected Serum Iron Concentration; AUClast in Fasted and Fed Conditions
Descriptive statistics of baseline corrected serum iron concentration; area under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Baseline Corrected Serum Iron Concentration; AUCinf in Fasted and Fed Conditions
Descriptive statistics of baseline corrected serum iron concentration; Area Under the Curve from 0-infinity by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Maltol Glucuronide; Cmax in Fasted and Fed Conditions
Descriptive statistics of Maximum plasma Concentration (Cmax) of plasma maltol glucuronide by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Maltol Glucuronide; AUClast in Fasted and Fed Conditions
Descriptive statistics of maltol glucuronide; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Maltol; Cmax in Fasted and Fed Conditions
Descriptive statistics of Maximum plasma Concentration (Cmax) of plasma maltol by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Maltol; AUClast in Fasted and Fed Conditions
Descriptive statistics of maltol; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of TSAT; Cmax in Fasted and Fed Conditions
Descriptive statistics of Maximum Concentration (Cmax) of transferrin saturation by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of TSAT; AUClast in Fasted and Fed Conditions
Descriptive statistics of transferrin saturation; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of TIBC; Cmax in Fasted and Fed Conditions
Descriptive statistics of Maximum Concentration (Cmax) of Total Iron Binding Capacity (TIBC) by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of TIBC; AUClast in Fasted and Fed Conditions
Descriptive statistics of Total Iron Binding Capacity (TIBC); Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Summary of Serious Adverse Events
Descriptive statistics of Serious Adverse Events by formulation (suspension or capsule) and condition (fed and fasted)
Time frame: up to 2 weeks following last dose
PK Analysis of UIBC; Cmax in Fasted and Fed Conditions
Descriptive statistics of Maximum Concentration (Cmax) of Unsaturated Iron Binding Capacity (UIBC) by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of UIBC; AUClast in Fasted and Fed Conditions
Descriptive statistics of Unsaturated Iron Binding Capacity (TIBC); Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1,1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Transferrin; Cmax in Fasted and Fed Conditions
Descriptive statistics of transferrin; Maximum concentration (Cmax) from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
PK Analysis of Transferrin; AUClast in Fasted and Fed Conditions
Descriptive statistics of transferrin; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
Time frame: Pre-dose and 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 10 and 24 hours post-dose
Treatment-Emergent Adverse Events
Treatment-Emergent Adverse Events from Day 1 to Day 22 (Study completion)
Time frame: From first dose of ferric maltol on Day 1 to study completion
TEAE Leading to Premature Discontinuation of Study Drug/PK Assessments
TEAE leading to premature discontinuation of study drug/PK assessments from Day 1 to study completion
Time frame: From first dose of ferric maltol on Day 1 to study completion
Vital Signs - Blood Pressure, Change From Day 1 to Day 8
Descriptive statistics for changes in blood pressure from Screening to Day 8
Time frame: Screening to Day 8
Vital Signs - Heart Rate, Change From Day 1 to Day 7
Descriptive statistics for changes in heart rate from Screening to Day 7
Time frame: Screening to Day 7
Summary of Received Concomitant Medication by Formulation
Number of participants having received concomitant medications by formulation (suspension or capsule)
Time frame: Day 1 to Day 8 (24 hrs post-dose of last dosing)
32 subjects recruited. 8 subjects randomised to each sequence.
| Milestone | Ferric Maltol Sequence A | Ferric Maltol Sequence B | Ferric Maltol Sequence C | Ferric Maltol Sequence D |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fasted condition between ferric maltol capsule and ferric maltol suspension.
| ratio | Ferric Maltol Capsule and Ferric Maltol Suspension in a Fasted Condition |
|---|---|
| Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted Condition | 69.94 (61.75 to 79.23) |
Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fed condition between ferric maltol capsule and ferric maltol suspension
| ratio | Ferric Maltol Capsule Fed and Ferric Maltol Suspension Fed |
|---|---|
| Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Combined Periods of Fed Condition | 99.11 (87.50 to 112.27) |
Ratio of area under the curve (AUClast) of total serum iron in combined periods of fasted condition between ferric maltol capsule and ferric maltol suspension
| ratio | Ferric Maltol Capsule Fasted and Ferric Maltol Suspension Fasted |
|---|---|
| Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fasted Condition | 77.54 (70.38 to 85.42) |
Ratio of area under the curve (AUClast) of total serum iron in combined periods of fed condition between ferric maltol capsule and ferric maltol suspension
| ratio | Ferric Maltol Capsule Fed and Ferric Maltol Suspension Fed |
|---|---|
| Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Combined Period of Fed Condition | 96.99 (88.04 to 106.86) |
Ratio of maximum serum concentration (Cmax) of total iron in fasted vs fed condition in 30mg ferric maltol capsule
| ratio | Ferric Maltol Capsule in Fed vs. Fasted Condition |
|---|---|
| Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Capsule | 147.27 (130.01 to 166.81) |
Ratio of area under the curve (AUClast) of total serum iron in fasted vs fed condition in 30 mg ferric maltol capsule
| ratio | Ferric Maltol Capsule in Fed vs. Fasted Condition |
|---|---|
| Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Capsule | 134.25 (121.86 to 147.91) |
Ratio of maximum serum concentration (Cmax) of total iron in fasted vs fed condition in 30mg (5ml) ferric maltol suspension
| ratio | Ferric Maltol Suspension in Fed vs Fasted Condition |
|---|---|
| Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted vs Fed Condition in Ferric Maltol Suspension | 103.93 (91.75 to 117.72) |
Ratio of area under the curve (AUClast) of total serum iron in fasted vs fed condition in 30mg (5ml) ferric maltol suspension
| ratio | Ferric Maltol Suspension in Fasted vs Fed Condition |
|---|---|
| Ratio of Area Under the Curve (AUClast) of Total Serum Iron in Fasted vs. Fed Condition in Ferric Maltol Suspension | 107.32 (97.41 to 118.24) |
Descriptive statistics of total serum iron concentration; Area Under the Curve (AUCinf) by formulation (suspension or capsule) and condition (fed and fasted)
| h*ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Total Serum Iron Concentration; AUCinf in Fasted and Fed Conditions | 2922.46 ± 1052.46 | 3694.05 ± 1561.138 | 3330.98 ± 2128.861 | 3445.41 ± 2615.954 |
Descriptive statistics of baseline corrected serum iron concentration; Maximum Concentration (Cmax), by formulation (suspension or capsule) and condition (fed or fasted)
| ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Baseline Corrected Serum Iron Concentration; Cmax in Fasted and Fed Conditions | 44.469 ± 73.0572 | 89.938 ± 50.9927 | 40.219 ± 52.9715 | 33.250 ± 23.0637 |
Descriptive statistics of baseline corrected serum iron concentration; area under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
| h*ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Baseline Corrected Serum Iron Concentration; AUClast in Fasted and Fed Conditions | 56.150 ± 964.9572 | 691.392 ± 791.8671 | 2.503 ± 889.0745 | -9.436 ± 693.2830 |
Descriptive statistics of baseline corrected serum iron concentration; Area Under the Curve from 0-infinity by formulation (suspension or capsule) and condition (fed or fasted)
No measurements were reported for this outcome.
Descriptive statistics of Maximum plasma Concentration (Cmax) of plasma maltol glucuronide by formulation (suspension or capsule) and condition (fed or fasted)
| ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Maltol Glucuronide; Cmax in Fasted and Fed Conditions | 3579.063 ± 1668.2120 | 5126.250 ± 1996.0748 | 3597.500 ± 1776.4390 | 7685.0 ± 1920.3797 |
Descriptive statistics of maltol glucuronide; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
| h*ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Maltol Glucuronide; AUClast in Fasted and Fed Conditions | 7335.93 ± 2449.530 | 9083.82 ± 2902.863 | 7802.52 ± 2585.848 | 10410.89 ± 2631.072 |
Descriptive statistics of Maximum plasma Concentration (Cmax) of plasma maltol by formulation (suspension or capsule) and condition (fed or fasted)
| ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Maltol; Cmax in Fasted and Fed Conditions | 16.994 ± 18.5420 | 20.531 ± 16.0714 | 33.600 ± 37.0501 | 34.656 ± 25.2179 |
Descriptive statistics of maltol; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
| h*ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Maltol; AUClast in Fasted and Fed Conditions | 28.61 ± 21.924 | 17.29 ± 15.274 | 39.13 ± 44.525 | 22.41 ± 16.879 |
Descriptive statistics of Maximum Concentration (Cmax) of transferrin saturation by formulation (suspension or capsule) and condition (fed or fasted)
| ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of TSAT; Cmax in Fasted and Fed Conditions | 32.750 ± 18.4793 | 43.031 ± 12.9428 | 30.344 ± 12.5970 | 30.188 ± 9.3892 |
Descriptive statistics of transferrin saturation; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
| h*ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of TSAT; AUClast in Fasted and Fed Conditions | 509.90 ± 201.915 | 644.62 ± 176.724 | 484.64 ± 153.990 | 513.62 ± 193.642 |
Descriptive statistics of Maximum Concentration (Cmax) of Total Iron Binding Capacity (TIBC) by formulation (suspension or capsule) and condition (fed or fasted)
| ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of TIBC; Cmax in Fasted and Fed Conditions | 393.688 ± 50.5208 | 394.781 ± 50.9913 | 396.938 ± 73.3577 | 394.656 ± 46.5310 |
Descriptive statistics of Total Iron Binding Capacity (TIBC); Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
| h*ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of TIBC; AUClast in Fasted and Fed Conditions | 8719.09 ± 1097.981 | 8880.52 ± 1165.547 | 8718.02 ± 1195.335 | 8878.43 ± 1069.977 |
Descriptive statistics of Serious Adverse Events by formulation (suspension or capsule) and condition (fed and fasted)
| Participants | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| Summary of Serious Adverse Events | 0 | 0 | 0 | 0 |
Descriptive statistics of Maximum Concentration (Cmax) of Unsaturated Iron Binding Capacity (UIBC) by formulation (suspension or capsule) and condition (fed or fasted)
| ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of UIBC; Cmax in Fasted and Fed Conditions | 329.750 ± 57.3298 | 323.250 ± 59.0172 | 331.250 ± 82.0668 | 322.375 ± 55.7018 |
Descriptive statistics of Unsaturated Iron Binding Capacity (TIBC); Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
| h*ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of UIBC; AUClast in Fasted and Fed Conditions | 6836.84 ± 1303.757 | 6432.85 ± 1052.589 | 6939.53 ± 1159.295 | 6978.71 ± 1182.131 |
Descriptive statistics of transferrin; Maximum concentration (Cmax) from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
| ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Transferrin; Cmax in Fasted and Fed Conditions | 304.063 ± 42.7332 | 302.594 ± 44.5051 | 300.688 ± 42.3316 | 303.031 ± 40.1670 |
Descriptive statistics of transferrin; Area Under the Curve from pre-dose to last measurable concentration by formulation (suspension or capsule) and condition (fed or fasted)
| h*ng/mL | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| PK Analysis of Transferrin; AUClast in Fasted and Fed Conditions | 6711.95 ± 965.632 | 6774.38 ± 948.865 | 6701.92 ± 980.522 | 6837.00 ± 936.103 |
Treatment-Emergent Adverse Events from Day 1 to Day 22 (Study completion)
| Participants | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| Treatment-Emergent Adverse Events | 0 | 2 | 3 | 3 |
TEAE leading to premature discontinuation of study drug/PK assessments from Day 1 to study completion
| Participants | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| TEAE Leading to Premature Discontinuation of Study Drug/PK Assessments | 0 | 0 | 0 | 0 |
Descriptive statistics for changes in blood pressure from Screening to Day 8
| mmHg | Sequence A | Sequence B | Sequence C | Sequence D |
|---|---|---|---|---|
| Diastolic blood pressure | -0.5 ± 3.02 | -0.3 ± 6.71 | -3.6 ± 7.58 | -2.4 ± 4.63 |
| Systolic blood pressure | -3.6 ± 6.25 | -4.6 ± 10.90 | -4.9 ± 14.59 | -0.1 ± 7.16 |
Descriptive statistics for changes in heart rate from Screening to Day 7
| beats/min | Sequence A | Sequence B | Sequence C | Sequence D |
|---|---|---|---|---|
| Vital Signs - Heart Rate, Change From Day 1 to Day 7 | -0.8 ± 10.26 | 8.1 ± 8.69 | 11.1 ± 11.23 | 3.1 ± 6.13 |
Number of participants having received concomitant medications by formulation (suspension or capsule)
| participants | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| Summary of Received Concomitant Medication by Formulation | 2 | 2 | 2 | 2 |
Collected over 8 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 30 mg Ferric Maltol Capsule in a Fed Condition | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| 30 mg Ferric Maltol Capsule in a Fasted Condition | 0/32 (0%) | 0/32 (0%) | 2/32 (6.3%) |
| 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| Event | 30 mg Ferric Maltol Capsule in a Fed Condition | 30 mg Ferric Maltol Capsule in a Fasted Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fed Condition | 30 mg (5 ml) Ferric Maltol Suspension in a Fasted Condition |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/32 | 1/32 | 0/32 | 2/32 |
| Vessel puncture site painGeneral disorders | 0/32 | 1/32 | 1/32 | 0/32 |
| RhinalgiaRespiratory, thoracic and mediastinal disorders | 0/32 | 0/32 | 1/32 | 0/32 |
| PruritusSkin and subcutaneous tissue disorders | 0/32 | 0/32 | 1/32 | 0/32 |
| Hypoaesthesia oralGastrointestinal disorders | 0/32 | 0/32 | 0/32 | 1/32 |
Overall demographic and baseline characteristics of the randomised population. The Randomized population is defined as all subjects who are randomized. The FAS is defined as all subjects who have had at least one dose of study drug and who have at least one evaluable post-dose PK sample.
| Age, Categorical(Participants) | Ferric Maltol Sequence A | Ferric Maltol Sequence B | Ferric Maltol Sequence C | Ferric Maltol Sequence D | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 8 | 8 | 32 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Ferric Maltol Sequence A | Ferric Maltol Sequence B | Ferric Maltol Sequence C | Ferric Maltol Sequence D | Total |
|---|---|---|---|---|---|
| Mean | 36.6 ± 9.33 | 34.00 ± 11.05 | 33.6 ± 6.44 | 40.5 ± 8.82 | 36.18 ± 8.90 |
| Sex: Female, Male(Participants) | Ferric Maltol Sequence A | Ferric Maltol Sequence B | Ferric Maltol Sequence C | Ferric Maltol Sequence D | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 5 | 15 |
| Male | 5 | 5 | 4 | 3 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Ferric Maltol Sequence A | Ferric Maltol Sequence B | Ferric Maltol Sequence C | Ferric Maltol Sequence D | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 8 | 8 | 7 | 6 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ferric Maltol Sequence A | Ferric Maltol Sequence B | Ferric Maltol Sequence C | Ferric Maltol Sequence D | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 6 | 5 | 5 | 24 |
| White | 0 | 2 | 3 | 3 | 8 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ferric Maltol Sequence A | Ferric Maltol Sequence B | Ferric Maltol Sequence C | Ferric Maltol Sequence D | Total |
|---|---|---|---|---|---|
| United States | 8 | 8 | 8 | 8 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Nov 2020, 1 month.
Results were first posted in Aug 2025, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric maltol
Shield Therapeutics